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ABSTRACT 
 
 
  
The purpose of this project is to investigate and assimilate information on a variety of 
topics related to stem cells, and determine the impact of this technology on society. In this report, 
the information is divided into four chapters to gradually lead the reader deeper into the topic. 
The first chapter is an introduction to stem cells and their sources. The second chapter is an 
explanation of the current and potential applications for stem cells in disease treatment. The third 
chapter delves into the ethical issues surrounding the stem cell debate. The fourth chapter 
examines the political policies involving stem cell research throughout the world, and the 
significance of the technology on society. Through comprehensive research it was concluded that 
stem cell research has the potential to be extremely advantageous to society. With current 
legislative practices in the United States under President Obama, stem cell research should have 
a strong impact on our culture.  
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PROJECT OBJECTIVES 
 
 
 The objective of this IQP project was to investigate the highly controversial topic of stem 
cells, and express opinions on the effect of this technology on society. Chapter-1 serves to 
introduce the reader to the topic of stem cells and describe their types, how they are classified, 
and how we currently isolate them. The purpose of Chapter-2 is to document the treatment of 
different diseases with stem cells in both animal model systems and in human clincial trials. 
Chapter 3’s purpose is to study the ethical debates raging within the global community on this 
topic, and relate the five world religions’ perspectives on the issue. Chapter 4 is dedicated to 
investigating the history of U.S. and International political policies and legislation governing 
stem cell research. Lastly, the author brings the report to a conclusion on the topic of the use of 
stem cells and which legislation best represents the overall views of the author on the topic. 
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Chapter 1: Stem Cell Introduction 
Types and Sources 
 
 
What are Stem Cells? 
 
Stem cells have the remarkable potential to develop into many different cell types in the body 
during early life and growth, and in the adult in many tissues they serve as a sort of internal repair 
system, dividing essentially without limit to replenish other cells as long as the person or animal is still 
alive. When a stem cell divides, each new cell has the potential either to remain a stem cell or become 
another type of cell with a more specialized function, such as a muscle cell, a red blood cell, or a brain 
cell. 
Stem cells are distinguished from other cell types by two important characteristics. First, they 
are unspecialized cells capable of renewing themselves through cell division, sometimes after long 
periods of inactivity. Second, under certain physiologic or experimental conditions, they can be induced 
to become tissue- or organ-specific cells with special functions.  In some organs, such as the gut and 
bone marrow, stem cells regularly divide to repair and replace worn out or damaged tissues.  In other 
organs, however, such as the pancreas and the heart, stem cells only divide under special conditions. 
Stem cells can be grouped into two main categories. These are Embryonic Stem Cells (ESCs) and 
Adult Stem Cells (ASCs).  Embryonic stem cells are present only during early development, whereas ASCs 
exist in fully grown organisms.  Stem cells can be further categorized based upon their relative potential 
to differentiate.  The first are totipotent cells. These have the ability to divide and produce all of the 
cells in an organism, including all cells of an adult organism and extra-embryonic tissue such as the 
placenta during pregnancy.  The human zygote is an example of a totipotent cell (Regenerative 
Medicine, 2009).  Totipotent cells can specialize into pluripotent cells.  Pluripotent cells can differentiate 
into all cells of an adult organism, but cannot form extra-embryonic tissue.  Embryonic stem cells are 
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pluripotent.  Pluripotent cells can differentiate into any of the three germ layers: endoderm, mesoderm, 
and ectoderm, which form all cells in the body.  From these cells, further specialization can occur to 
form multipotent cells.  These cells usually differentiate into groups of related cell types.  For example, 
multipotent hematopoietic stem cells form all the cellular components of blood, but do not usually form 
other unrelated cells.  Mesenchymal stem cells are also multipotent.  Multipotent cells have the 
potential to differentiate into unipotent cells that form only one type of cell with a specific function.  
The most common unipotent cells are skin cells. 
 
Embryonic Stem Cells 
Embryonic Stem Cells (ESCs) are pluripotent cells derived from the inner cell mass of a 5 day old 
blastocyst.  The blastocyst (Figure-1, upper center) is a hollow ball of cells about the size of the period at 
the end of this sentence,  made up of the blastocoel cavity, the trophoblast cells lining the embryo, and 
the inner cell mass (Figure-1, blue cells).  The inner cell mass cells are undifferentiated, and can give rise 
to any cell in the body via the three germ layers (Figure-1, lower diagram).   
ESCs used in research are usually derived from in vitro fertilized (IVF) embryos.  Once a family is 
done using them, the excess embryos are usually discarded, so discarded IVF embryos are the primary 
source of ESCs for research.  The fertilized embryos are grown in a test tube to about day-5 to form the 
blastocyst.  The inner cell mass cells are then obtained using a micro-syringe, and can be cultured in vitro 
for years making an embryonic stem cell line.  Mouse ESCs injected into another mouse blastocyst have 
been shown to differentiate into all types of cells of the adult mouse.  Throughout their life, ESCs 
maintain the ability to give rise to all body cell types.  Scientists are currently devising protocols for 
differentiating ESCs into various tissues in vitro.   
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Figure 1: Characteristics of Embryonic Stem Cells.  ESCs are derived from the 
inner cell mass (blue) of a blastocyst embryo (pink), and can self-renew 
(diagram middle), or can differentiate into all three types of germ layers 
(diagram lower).   (Winslow, 2006). 
 
Mammalian ESCs were first derived in 1981, when Martin Evans and Matthew Kaufman isolated 
pluripotent cell lines from cultures of mouse blastocysts.  It took 18 years for the first human ESC 
derivations to be reported (Thomson et al., 1998). ESCs are created from excess IVF embryos.  Oocytes 
and sperm are placed together in a culture dish to allow fertilization to occur outside the body. The cells 
divide for 5 days to form the blastocyst, from which the inner cell mass ESCs are isolated.  The ESCs 
divide to cover a petri dish pre-coated with a “feeder cell” layer.  This layer of cells provides the ESCs 
with essential growth factors and also provides a surface to stick to.  The feeder cells were originally 
made up of mouse fibroblasts in bovine serum (Kirchstein and Skirboll, 2001), but due to scientific and 
ethical concerns of co-culturing human cells with animal cells more recently a “feeder-free” human ESC 
 8 
culture system has been developed to minimize the possibility of animal pathogen introduction into the 
cell culture.  This process involves placing the ESCs onto easily sterilizable extracellular matrix (ECM)-
coated plates (Klimanskayza et al., 2006). 
Even though ESC derivation and culture conditions have been established, the efficiency of 
deriving human ESCs is still very low compared to mouse.  The ideal growth medium would be easy to 
use, inexpensive, and would contain growth factors to minimize the rate of genetic and epigenetic 
changes in culture (Regenerative Medicine, 2006).  
 
Adult Hematopoietic Stem Cells 
Adult stem cells are somewhat rare in the human body compared to the differentiated cell 
population.  However, Hematopoietic Stem Cells (HSCs) are the most common type of adult stem cells. 
HSCs are found in the bone marrow (Figure-2, left side) and spleen, and are normally used by the body 
in the formation of new blood cells, both red (diagram center) and white (diagram upper center and 
upper right).  Only an estimated 1 in 15,000 cells in bone marrow is a HSC (Weissman, 2000). These cells 
are defined by their ability to self-renew and differentiate into all types of blood cells in the body.  Red 
cells are used in the distribution of food, oxygen, and waste throughout the body. White blood cells 
come in various forms, and are all used for immunity from pathogens.  
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Figure 2: Diagram of Hematopoietic and Stromal Stem Cell Differentiation.  Bone marrow (left 
side) is the most common source of HSCs (pink cell diagram center).   HSCs can form all the 
cellular components of blood, including red blood cells (red cells diagram center), and white 
blood cells (diagram upper center and upper right).  (Regenerative Medicine, 2006). 
 
The majority of HSCs are found in bone marrow, and these cells have been used for over 30 
years in bone marrow transplants (discussed in Chapter-2).  HSCs can also be obtained from umbilical 
cord blood, or from the peripheral blood stimulated with cytokines to mobilize the HSCs from the 
marrow.  Due to the relative ease of isolation, the cytokine mobilization procedure is generally replacing 
bone marrow as the preferred source for HSCs. 
Over the past 40 years, scientists have attempted to identify surface protein markers that 
distinguish HSCs from other cell types.  Scientists currently believe that HSCs express c-kit, CD34, and H-
2K proteins on their surface.  Two types of HSC have been defined from these isolations: long-term and 
short-term HSCs.  Long-term HSCs propagate the entire lifetime of an animal, and have high levels of 
telomerase activity (an enzyme found in long lived cells that helps them maintain long telomere ends of 
their chromosomes).   Short-term HSCs may only propagate for a few months, and can differentiate into 
lymphoid and myeloid precursors for the two major lineages of blood cells.  Though HSCs have been 
 10 
shown to propagate in vivo, scientists have not been able to easily induce their growth in vitro 
(Regenerative Medicine, 2006), although some success has recently been achieved for the in vitro 
propagation of human umbilical cord blood HSCs (Viacell, 2008).  
 
Adult Neuronal Stem Cells 
Adult Neuronal Stem Cells (NSCs) are cells that can generate neural tissue and possibly repair 
the nervous system. These cell types were discovered while studying the development of blood cells. 
Stem-like cells were originally isolated from the embryonic central and peripheral nervous systems, but 
recently stem-like cells have also been isolated from the adult brain.  NSCs have been found in the 
hippocampus and the sub-ventricular zone (SVZ) as well as the spinal cord (Figure-3).  Because the 
surface markers that define central nervous system stem cells are still being developed, they are 
currently identified based upon their activities after separation (Temple, 2001). 
 
Figure 3: Principal Regions of the Adult Nervous System 
Containing Neuronal Stem Cells (Temple, 2001). 
 
 
The plasticity of NSCs has been examined by transplanting them directly into embryos and 
examining which neural cells are produced.  Spinal cord-derived NSCs can make neurons if injected into 
the adult hippocampus (Shihabuddin et al., 2000), but there is no direct evidence that NSCs can make 
neurons similar to those derived from ESCs. 
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 Adult Cardiac Stem cells 
 
Until recently, the adult heart has been thought of as an organ without regenerative capacity.  
However, in the past few years cycling ventricular myocytes have been documented in adult mammalian 
hearts (Quaini et al., 2002). During cardiac transplants between different-sex humans, some cardiac 
chimerism was displayed in which new male cells occurred in the transplanted female heart presumes 
the existence of stem-like cells able to differentiate into the three main cardiac cell types.  Primitive cells 
that expressed antigens c-kit, Sca-1, and MDR1, frequently associated with stem cells, were identified in 
both the recipient and control hearts, thus these cells may be true cardiac stem cells, but the exact 
lineage of these cells is still unknown (Beltrami et al., 2003). 
Researchers at New York Medical College in Valhalla identified pockets of stem cells in the 
interstices between the muscle cells in rodent hearts.  They also examined humans who had undergone 
cardiac surgery and found very similar stem cells that had been attempting to repair the heart damage 
(Urbanek et al., 2003).  The presence of these cells strongly suggests that the heart retains a stockpile of 
stem cells to repair damaged tissue (Touchette, 2004).  Figure-4 shows these cardiac stem cells located 
between human heart cells. 
 
 
Figure 4:  Photograph of Cardiac Stem Cells.  The cardiac stem cells are stained blue, 
while the cardiac muscle cells are stained red.  (Urbanek et al., 2003) 
 
Adding to these past discoveries, Kenneth Chien, at the Keystone Symposium on Molecular 
Pathways in Cardiac Development and Disease, in Breckenridge, CO, took the findings a significant step 
forward.  His team found an early multipotent embryonic cardiovascular cell expressing protein Isl1 and 
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that can give rise to the three cardiac lineages:  cardiac myocytes, smooth muscle cells, and endothelial 
cells, as shown in Figure-5 (Moretti et al., 2006).  
 
 
Figure 5: Cellular Hierarchy of Cardiac Progenitors and Their Lineage 
Specification.  Multipotent cardiovascular progenitor cells (green cells, diagram 
center) give rise to all 3 lineages of cardiac cells (diagram right). (Moretti et al., 
2006) 
 
 
Adult Epithelial Stem Cells 
 
Adult epithelial stem cells can be found in several places.  The epithelium proliferates at a very 
rapid pace.  There is evidence to support that epidermal cells are replaced by division from stem cells.  
For example, in hair follicles scientists believe the epidermis is organized hierarchically, with stem cells 
found near the “bulge” midway down the follicle (Figure-6).  Because stem cells are slow-cycling and 
highly proliferative during development they can be identified in vivo by labeling the cells with 3H-TdR . 
This protocol is widely used to monitor rates of cell proliferation (Smits & Riemann, 1988). After 4-6 
weeks, because of their slow-cycling nature, only the stem cells remain, which can then be identified 
with immunohistology. The label-retaining cells are present both in the epidermis and hair follicle 
(Cotsarelis et al., 1999).  
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Figure 6: Cutaneous Epithelial Stem Cells.  Epithelial stem cells in the bulge of the 
hair follicle give rise to at least 4 progenitor types.  EPC: epidermal progenitor 
cell; EPU: epidermal proliferative unit; SC: Stem cell ; HPC: hair progenitor cell 
(Cotsarelis et al., 1999). 
 
Another place epithelial stem cells are found is the lining of the colon. These cells give rise to 
several cell types, and are controlled by interactions between mesenchymal cells and epithelial cells.  
 
Mesenchymal Stem Cells 
 
Adult mesenchymal stem cells (MSCs) are categorized as multipotent cells, and are found mainly 
in the bone marrow of humans.  Residing primarily in the stromal area of the bone marrow, these cells 
have been shown to differentiate into many types of cells such as osteoblasts, chondrocytes, and 
adipocytes (Figure-7).  MSCs have also been isolated from a wide range of tissues, including peripheral 
blood, adipose tissue, trabecular bone, and even amniotic fluid.  Isolation of MSCs is currently done by 
sorting bone marrow populations by flow cytometry to various antibodies.  MSCs have been shown to 
be very versatile, even with the potential to repair tissues outside the mesenchymal lineage.  Due to 
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their multilineage potential, and their relative ease of isolation, MSCs are becoming increasingly popular 
for cell therapy experiments, but further research will be necessary to more fully define their  potential 
(Jackson et al., 2007).  
 
Figure 7: Mesenchymal Stem Cell Lineage (HemoGenix, 2009) 
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Chapter 2: Stem Cell Applications 
Diseases and Treatments 
 
 
Stem Cell Application Introduction 
 
The idea of growing personalized organs from one’s own cells, or healing spinal cord injuries, 
was once a pipe dream.  Now because of advances in science today, stem cells are being used in 
applications ranging from treating diabetes, leukemia, and Parkinson’s disease, to repairing damaged 
heart tissue and bone marrow (Flanagan, 2007).  In addition, there is much confusion in the press about 
what has in fact been done with stem cells, versus what remains for future applications.  The purpose of 
this chapter is to accurately summarize what has been done with stem cells for certain diseases, while 
especially distinguishing fact from hype. 
There is a strong debate raging in bioethics today about using embryonic stem cells (ESCs) to 
cure diseases, yet not one human patient has been cured to this day using these cells.  Adult stem cells 
(ASCs) are readily available from many sources, as discussed in the previous chapter, and provide 
concrete results with patients today.  While the successes of adult stem cell treatments are becoming 
clear, treatments with embryonic stem cells have either not received approval for testing, or have not 
shown any clinical successes (Sipione et al., 2004).  Currently, upwards of 70 diseases and disabilities are 
treatable using non-embryonic stem cells (Earll, 2005).   For example, in 2001, 11 out of 15 Type I 
diabetes patients were successfully removed “completely off insulin” after receiving transplants of adult 
pancreatic cells (Cell grafts, 2001).  In 2002, a California man with Parkinson’s disease experienced more 
than an 80 percent reduction in his symptoms after receiving an injection of his own neuronal stem cells 
(Stem cell transplant, 2002).  In 2003, patients with heart failure saw significant improvements after 
receiving infusions of their own bone marrow stem cells, and four out of five seriously sick Brazilian 
heart-failure patients no longer needed transplants after being treated with their own bone marrow 
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stem cells (Perin et al., 2003).  While these human cases have been documented in clinical trials, many 
other diseases are in the process of being cured through animal studies and non-human trials (Hughes, 
2005).  
 
Treating Diabetes with Stem Cells 
 
Diabetes is a terrible disease that reaches worldwide, affecting millions of people. There are two 
major forms of diabetes: type I and II. Type I diabetes is an autoimmune disorder that destroys the β-
cells of the pancreas.  These cells produce insulin, a hormone that modulates blood glucose 
concentration in the blood. Type I diabetes usually begins in childhood, and eventually results in a 
complete dependence on exogenous insulin treatments (Assasy et al., 2005).  Type II diabetes, the more 
common of the two, is characterized by tissue resistance to insulin; eventually the cells cannot produce 
enough insulin to overcome the resistance (Goldthwaite, 2006). Type II diabetes is a metabolic disorder 
that, unlike type I, is largely preventable.  An active lifestyle and a healthy diet are often enough to 
prevent the onset of type II diabetes. 
Diabetes poses a significant health issue for the world. According to the International Diabetes 
Federation, the disease affects nearly 250 million people, 7% of the world’s population. This number is 
expected to rise to 380 million by 2025 due to aging populations, obesity, and sedentary lifestyles 
(Table- 1) (International Diabetes Federation, 2007).  It is currently the sixth leading cause of death in 
the U.S., and is associated with many health complication including heart disease, stroke, kidney 
disease, blindness, and amputations. To put it into a bigger perspective, the American Diabetes 
Association estimates that 1 in 10 health care dollars currently spent is used for diabetes (American 
Diabetes Association, 2008).  
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Table 1:  Summary of the Worldwide Diabetes Population.  Estimated 
numbers (in thousands) of people with diabetes by world region for 2000 and 
2030, and summary of population changes (Wild et al., 2004). 
 
 
Because there is presently no cure for diabetes, there is extreme interest in exploring stem cells 
as a possible therapeutic option. Theoretically, stem cells could be used as a treatment by growing a 
population of β-cell precursor cells from donor tissue and then inducing differentiation in vitro into 
insulin-producing cells for transplant into the patient’s liver (Lechner & Habener, 2003).  Thus, much 
recent research has focused on the possibility of harvesting adult pancreatic stem cells.  The key step for 
using stem cells to treat diabetes is to identify the precursor cells that give rise to β-cells.  Animal studies 
are the first step to this identification. Several recent studies in rodents have shown that the pancreas 
contains rare endocrine progenitor cells that can differentiate into β-cells (Soria et al., 2005).  Raewyn 
Seaberg and his associates identified multipotent precursor cells in the adult mouse pancreas that could 
proliferate in vitro and could differentiate into pancreatic β-cells that demonstrated glucose-dependent 
insulin release, so these cells could have therapeutic applications for diabetes (Seaberg et al., 2004).  
However, in contrast to this finding, Dor used genetic lineage tracing in mice to conclude that new β-
cells arise from pre-existing β-cells rather than from pluripotent stem cells in adult mice (Dor et al., 
2004).  Thus despite much research, it is still not known conclusively whether new β-cells arise from 
existing β-cells or from pancreatic stem cells.  But in either case, so long as culture conditions can be 
established for replicating the β-cells regardless of their origin, such cells could be used for therapy. 
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With respect to using embryonic stem cells to treat diabetes, some success has been reported 
treating mouse diabetic models with pancreatic-like cells differentiated from ES cells (Soria et al., 2002).  
And in humans, ES cells have been induced to secrete insulin in a glucose-dependent manner (Assady et 
al., 2001; Lumelsky et al., 2001; D’Amour, 2006), but these cells have not yet been used to treat human 
patients. 
Since an adult pancreatic stem cell population has not convincingly been identified, and since 
the β-like cells derived from ES cells have not been approved for human use, there are currently no stem 
cell diabetes clinical trials underway.  While stem cells must currently be considered a frontier for 
diabetes therapy, hopefully one day they will become its foundation.  
 
Treating Cardiovascular Disease with Stem Cells 
 
Cardiovascular disease (CVD) includes hypertension, coronary heart disease (CHD), stroke, and 
congestive heart failure (CHF), and has ranked as the number one cause of death in the United States 
nearly every year since 1900 (American Heart Association, 2005).  Heart failure occurs when cardiac 
tissue is deprived of oxygen.  When this deprivation is severe enough to cause the loss of many cardiac 
muscle cells, it often begins a slippery slope of problems including the formation of non-contracting 
tissue and the thinning of the ventricular wall to eventually cause heart failure and death (Rosenstrauch 
et al., 2005).  The aging U.S. population and other cardiovascular risk factors suggest that CVD is going to 
continue be an important health concern in the near future, thus there is clearly a need for therapies to 
regenerate or repair damaged cardiac tissue.  
There are currently many approaches to combat heart disease, but none have been able to 
completely solve the associated problems.  Beta blockers, diuretics, and angiotensin-converting enzyme 
inhibitors, as well as implanting assistive devices like defibrillators and pacemakers, do not repair the 
damaged tissue and only lessen the detrimental effects of lost cardiac function.  In addition to these 
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partial therapies, heart transplants are really the only way to replace damaged cardiac tissue but pose 
problems such as organ rejection.  Thus, researchers have begun exploring other options, including 
using stem cells for cardiac repair (Goldthwaite, 2006).  
Many different types of stem cells have been tested, including embryonic stem cells, skeletal 
myoblasts (SM), mesenchymal (bone marrow stromal) stem cells, and resident cardiac stem cells, and 
some have shown impressive results.   Studies in both rats and humans have shown that skeletal 
myoblasts can repopulate scar tissue and improve left ventricular function after transplantation (Dowell 
et al., 2003), but transplanted SM cells do not contract in complete sync with the rest of the cardiac 
tissue.   
With respect to stem cells, an experiment in swine using transplanted mesenchymal stem cells 
indicated that over 60% of the damaged area was repaired (Shake et al., 2002).  Due to the success of 
treating animal heart attack models with stem cells, a wide range of clinical studies have been 
performed over the past few years.  Reports have shown that patients with heart attacks have been 
successfully treated with adult cardiac stem cells (Britten et al., 2003; Randerson, 2003; Siminiak et al., 
2004), mesenchymal stem cells (Schächinger et al., 2006), and bone marrow stem cells (Lunde et al., 
2006; Schächinger et al., 2006).  With respect to embryonic stem cells, studies have shown that human 
ES cells can differentiate into cardiac lineages (Kehat et al., 2001), but ES cells have not yet been tested 
in clinical trials for heart attack patients.   Hopefully in the near future, more clinical trials can be 
performed to get a better understanding of the potential for using stem cells to treat this terrible 
disease.  
 
Treating Parkinson’s Disease with Stem Cells 
 
 Parkinson’s disease is the second most common form of neurological disease.  It is caused by the 
progressive loss of the dopaminergic (DA) neurons (Figure-8) in the brain that release dopamine 
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involved in neuronal communication, especially as related to muscular function.  When these 
dopaminergic cells are destroyed, many symptoms begin to develop including tremor, rigidity, 
hypokinesia (decreased muscle activity), and difficulties with balance and walking.  Currently, 
Parkinson’s disease is treated with medications containing dopamine replacements, but these 
medications only temporarily treat the symptoms, and do not slow or prevent the natural progression of 
the disease (Garfinkel, 2005).  The average age of onset for all forms of Parkinsonian syndromes is about 
60, and as the population ages the cases in the U.S. are expected to double from 350,000 to 600,000 by 
2030 (Dorsey et al., 2007).  
 
Figure 8: Diagram of Parkinson’s Disease.  The figure shows the differences in 
brain signal transmission for a healthy brain (left panel) versus a a brain 
affected by Parkinson's Disease (PD) (right panel).  Note that in PD, the lack of 
dopamine secretion (dark yellow) removes the dampening effect on the 
reticular formation (light blue) from the basal ganglia (light yellow).  (Holistic 
Online, 2007) 
 
To treat PD with stem cells, the problem is to identify and develop stem cell lines that 
differentiate into precursors for DA neurons.  Some success has been achieved in animals and humans 
grafting embryonic DA neurons from aborted fetal tissue (Madrazo et al., 1988; Lindvall et al., 1989; 
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Quinn, 1990; Freed et al., 2001, Mendez et al., 2002), but such studies have been discontinued in the 
U.S. and many countries due to strong ethical concerns.   With respect to adult stem cell treatments for 
PD, human PD patients have successfully been treated with adult olfactory mucosal stem cells 
(Levesque, 2005), but few other studies have been successful.   
With respect to treating PD with embryonic stem cells, ES cell suspensions grafted into rodent 
striatum (the inner part of the cerebrum in the brain), differentiated into adult DA neuronal cells after 
transplantation in vivo (Björklund et al., 2002).  Redmond and colleagues have extended the ESC 
approach into primates, showing that the microenvironment of the diseased brain can strongly 
influence the phenotype of the transplanted cells (Capone et al., 2007).   This group transplanted 
undifferentiated human neural cells instead of predifferentiated dopamine precursors into Parkinsonian 
primates and the apes showed remarkable improvements in symptoms (Redmond et al., 2007).  
Allowing the brain to determine the fate of the donor cells and their corresponding reparative 
properties may, in fact, be a key step in a successful stem cell therapy for Parkinson's patients (Sanberg, 
2007).   
No Parkinson’s patients have been treated yet with ES cell therapy, however human ES cells 
have been shown to differentiate into dopamine-producing cells in vitro (Perrier et al., 2004). For clinical 
trials, the potential for tumor formation and inappropriate stem cell migration must be minimized 
before any Parkinson’s patients are enrolled in clinical trials (Sanberg, 2007). Significant further 
preclinical testing on primates must occur to demonstrate safety and efficacy before human clinical 
trials can begin.   
 
Treating Leukemia with Stem Cells 
Leukemia is a group of bone marrow diseases which involve an uncontrolled increase in 
immature nonfunctional white blood cells (leukocytes).  Leukemia is often called blood cancer because 
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of the uncontrollable growth of these leukocytes.  Every ten minutes, someone dies from leukemia or a 
related blood cancer, which translates to almost 150 people per day.  Current treatments include drug 
and radiation therapy to destroy the rapidly dividing cells, immunotherapy to induce antibody formation 
against the leukemic cells, gene therapy to correct a genetic defect causing the proliferation, and stem 
cell transplantation to re-grow healthy leukocytes.  Several new drugs have been introduced in the past 
decade that have greatly improved remission rates for many people, but some of these drugs destroy 
healthy cells and do not rebuild lost tissue (Leukemia & Lymphoma Society, 2009). 
Hematopoietic stem cells (HSCs) have been used clinically in humans since 1959 to treat 
hematopoietic cancers (leukemias and lymphomas), to recover from the use of high-dose 
chemotherapy, or to treat other diseases such as aplastic anemia, thalassemia, sickle cell anemia, or 
autoimmune diseases (Horowitz, 1999; Santos, 2000).   Thus, HSCs are the most characterized type of all 
stem cells.  Currently, about 40,000 transplants are performed annually world-wide.  HSC 
transplantation is a very important therapy leukemia because HSCs are used to restore the function of 
the bone marrow that has been damaged either from the cancer or the previous drug treatments.  Most 
types of stem cell transplants for treating blood cancer are autologous, which means that the patient 
has his or her own cells harvested and then infused back into the body following radiation treatment or 
chemotherapy (Figure-9).  HSCs are most often harvested from the patient’s bone marrow. 
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Figure 9:  Diagram of Autologous Bone Marrow Transplantation of 
Hematopoietic Stem Cells.  Bone marrow containing hematopoietic stem cells is 
harvested from the patient’s hip bone, then given back to the same patient after 
the leukemia cells in the patient's bone marrow have been destroyed with 
chemotherapy or irradiation (Lavelle, 2004). 
 
Although bone marrow is the most frequent source for obtaining HSCs, other alternatives have 
been discovered as viable options, including the use of umbilical cord blood or HSCs mobilized into the 
peripheral blood using hormones.  In 2004, a study published in the New England Journal of Medicine 
confirmed that stem cells derived from the umbilical cords of babies are a useful and effective 
transplant source for leukemia patients without matched relatives.  An analysis and comparison of 
treatment results in over 500 patients was conducted, and the results showed a significantly improved 
survival rate over those who did not receive cord blood (University Hospitals of Cleveland, 2004).  
Ongoing research into leukemic cells and their origins has brought on new knowledge and 
theories.  We now know that bone marrow is the primary site of leukemic relapse.  One very important 
component in the marrow is the mesenchyme containing mesenchymal stem cells (MSC).  These cells 
have been demonstrated to protect and shield leukemiccells from apoptosis (Gibson, 2002), so some 
research is focusing on how to induce MSCs to kill leukemic cells.  In a recent study, researchers found 
 25 
that blocking a specific signaling pathway, PI3K-Akt-Bad, in MSCs may remove the shielding effects, and 
help them kill leukemic cells (Wei et al., 2009).  
These are only a few of the advances in treating leukemia recent years, but many other new 
treatments are under study in clinical trials to help a growing number of patients achieve remission.  
 
 
Chapter-2 Conclusion 
 
Although many problems have been solved through stem cell research with regards to the 
treatment of diabetes, damaged cardiac muscle, Parkinson’s disease, and Leukemia, there still remain 
many unanswered questions.  Most of the human applications of stem cells involve the use of adult 
stem cells of various types since these cells have fewer ethical concerns than ESCs.  Only time and more 
research will tell how well the treatments will work and which stem cells, if any, are best for combating 
specific diseases. There is a vast world of knowledge of which we have just begun to graze the surface in 
the applications of stem cells.  Hopefully, with the current favorable political atmosphere and the recent 
removal of tight regulations for federal support of ESC research, researchers now have all the tools at 
their disposal to explore new applications.   
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Chapter 3:  Stem Cell Ethics 
 
World Religions and Stem Cells  
 
 
Introduction 
 
 Stem cell research is important if the medical world wishes to be able to repair damage within 
the human body.  The past few decades have seen stem cell research develop in amazing ways, many of 
which are advantageous to society (as discussed in Chapter-2).  But an extremely heated debate still 
rages over the use of embryonic (ES) stem cells.  And the public often lumps all stem cell types together 
confusing adult stem cells with ES cells.  The purpose of this chapter is to discuss the ethics of stem cell 
use, both adult and embryonic, especially focusing on various religious stances.  It is the goal of this 
chapter to delve into the particular views of the five major world religions, specifically Christianity, 
Judaism, Islam, Buddhism, and Hinduism. 
 Although both sides of the stem cell dispute have voiced very compelling arguments, the issue is 
still embroiled in ethical controversy. The way that ES cells are obtained is central to the debate because 
when ES cell lines are created a 5-day old human embryo is destroyed.  Thus, the ES cell debate 
eventually focuses on when life begins.  Those in support of ES cell research say that the moral status of 
an early human embryo (5 day old blastocyst) is equivalent to any other cell in the human body, so 
destroying it to obtain ES cells is acceptable, especially when trying to save human lives. Those opposed 
to ES research state that the embryo is a human life from fertilization, the destruction of which they 
consider murder or abortion (Nisbet, 2004). The problem is that both sides believe they are right and 
that the other side is wrong. Who should we believe? Is there a way to reach a compromise between the 
two groups? These questions have created a basis for religious and secular arguments worldwide.          
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 When debating the issue of when life begins, each of the world’s major religions have their own 
accounts.  Many religious leaders have voiced their stances on the issue of embryo and ES cell research. 
For those individuals who inadvertently group all stem cell types into one category, it is important to 
note that no major world religion is against using adult stem cells, so long as they are used to try to save 
human lives.  While using adult stem cells is a relatively placid topic, there is really no consensus 
between religions on the acceptability of using embryos or ES cells for research.  Because religions have 
a duty to respect and protect human life as well as prevent and alleviate suffering, a tension is created in 
balancing embryonic stem cell use with the diseases they might cure.  Most opinions that deal with the 
morality of ES cell research are based upon whether blastocysts are viewed as persons. Some believe 
that the early embryos are human persons with human rights from the moment of conception, while for 
others the embryo does not reach this stage until anywhere from 40 to 120 days after conception 
(Knowles, 2009).   
 An important point when considering religious views on stem cells is although a particular 
religion may hold a particular overall belief, no religion is strictly monolithic and there are many groups 
within each religion that may hold contradicting viewpoints.  Thus, although a particular religious leader 
may hold one stance, other leaders within the same religion may hold different stances. 
 With respect to the ES cell debate, it is also important to note the source of the embryos used to 
derive the ES cells.  As discussed in Chapter-1, ES cells are derived from 5-day old blastocysts prepared 
by in vitro fertilization (IVF).  During IVF, parents donate sperm and eggs to an IVF clinic, and then the 
IVF is performed in a test tube.  The newly fertilized embryos are grown 5 days to blastocysts and stored 
in liquid nitrogen until use.  After the parents have enough children, the excess embryos previously 
prepared are usually discarded, and it is these discarded embryos (originally prepared for reproductive 
purposes) that remain the only legal source of embryos for research in the U.S. even under Obama’s 
current favorable legal policies. 
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Christianity and Stem Cells 
 
 Christianity is the world’s largest religion, and within it are multiple viewpoints on embryo 
research. The official position of the Catholic Church on ES cells is that personhood begins at conception 
(Catholic Online, 2008). This is taken to mean that the human embryo has the same moral status as a 
human person, and deserves the same right to life.  Basically it does not matter what the embryos are to 
be used for, the end does not justify the means, and the act of killing the embryo at any stage in life is 
deemed immoral and unacceptable.  However, the Catholic Church wholeheartedly endorses the use of 
adult stem cells, also called somatic stem cells, for research (Smith, 2006; Pope Benedict XVI, 2007).  
Pope Benedict XVI encouraged those working in Catholic scientific institutions to increase somatic stem 
cell research and “to establish closer contact among themselves and others who seek to relieve human 
suffering through moral means” (Catholic Online, 2008).  
 Many members of the Catholic Church have spoken out against embryonic stem cell research. 
Perhaps the most major outcry happened in 2001.  In response to President Bush’s decision to allow 
limited federal funding for embryo stem cell research, Bishop Joseph A. Fiorenza issued a statement 
calling the decision morally unacceptable. Pittsburgh Bishop Donald Wuerl also stated that “While a 
stem cell is a tiny speck, it nonetheless contains the elements out of which comes the fully developed 
human person (American Catholic Organization, 2006).” 
 As is typical of large religions, multiple viewpoints can exist, and this is the case with Christianity.  
While the Catholic Church is clearly against embryo research, other denominations within Christianity, 
such as the Unitarian-Universalists, the Episcopal Church, the Evangelical Lutheran Church, the United 
Methodist Church, and the Church of Jesus Christ of Latter Day Saints, have no official position 
(Derbyshire, 2001). 
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Judaism and Stem Cells 
 
 Contrary to the Catholic religion, Orthodox Jews believe that early embryos do not have the 
same moral status as full human persons. These views are influenced by both biblical and Talmudic 
(rabbinical law) (Teaching about Religion, 2006).  Actually, under Jewish law, human embryos outside a 
human body do not have any rights (Knowles, 2009). Under Jewish Law (Halcha) the fetus does not 
become a person (nefesh) until the head emerges from the womb. According to the Talmud, during the 
first forty days of gestation, the embryo is “simply water”. Thus, the fetus is only considered “holy” from 
the 41st day after conception until birth.  During this early period, the Rabbis consider the fetus as the 
“thigh of its mother.” Neither men nor women may amputate their thigh because according to the Bava 
Kamma, “Our bodies belong to God and hence we are forbidden to inflict injuries upon ourselves.” This 
is specifically the period in which the embryo begins to gain its rights (Dorff, 2000).  Rabbinical opinions 
suggest that the embryo does not reach fetal status until it is implanted in the uterus.  Prior to that 
implantation, such early embryos have no independent real-life potential, and they are not considered 
alive.  Consequently, there would be no Jewish legal opposition to disposing of them, researching on 
them, or deriving stem cell tissue from them (Jakobovits, 2006).   Accordingly, there would also be no 
Jewish legal problem using stem cells derived from adult tissues. 
 In addition to believing an individual’s full rights begin at birth not conception, normative Jewish 
law encourages medical interventions to correct both congenital and acquired defects.  Thus, many in 
Judaism consider it morally wrong not to try to save lives with stem cells.  Following these views, 
Judaism supports ethically justifiable research using embryos for research and therapeutic purposes 
(Teaching about Religion, 2006).  
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Islam and Stem Cells 
 
 Islamic countries have been involved in stem cell research for several years.  Unlike common 
perceptions, they are actually more flexible when it comes to human ES cell research than religions such 
as Catholicism, because the status of the embryo is different than it is in Christianity.  Muslims in Iran, 
Turkey, Singapore, and other Islamic countries believe that full human life, including the rights of a 
human person, do not begin until after the “ensoulment” of the fetus. Muslim scholars believe this 
ensoulment to take place at 120 days after conception (well after the 5 day old blastocyst). In addition, 
the importance of preventing human suffering and illness articulated in the Quar’an (similar to Judaism) 
means that it is immoral not to try to prevent human suffering, which adds weight to using the surplus 
IVF embryos for stem cell research.   
 And as is typical of any large religion, various viewpoints exist within this one religion.  Among 
the Muslim community, many different religious leaders and scholars present their opinions, but there is 
no singular individual or group that exercises a high authority in all matters of practice (Walters, 2004).  
Because of the belief that personhood is an ongoing developmental process, the majority of Sunni and 
Shiite jurists support ethically regulated stem cell research (Teaching About Religion, 2006), and it is 
generally encouraged if it is being done to produce tissues, valves, and new organs ultimately for 
treatment purposes (Bhikkhu, 2007).  
 
Buddhism, Hinduism and Stem Cells 
 
 Hinduism is a principal Asian religion that encompasses a vast range of traditions and beliefs. 
Hinduism has a lot in common with Buddhism, so they are discussed together here.  There is no real 
central authority in either religion that can pronounce unified positions on stem cell research, and there 
is also no authority that directly addresses the morality of the research.  However, because a 
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fundamental tenet of both religions is the importance of practicing compassion towards others, medical 
research involving adult stem cells to help others is widely accepted (Knowles, 2009). 
 For these religions, as with the other main world religions, ES cell research is a controversial 
topic.  Hindus consider the human embryo to be a person at the moment of conception, because it is 
the beginning of a soul’s rebirth from a previous life (Castillo, 2006).  In Hinduism, another central tenet 
is the mandate to avoid harming other living things. This tenet discourages ES cell research because the 
embryo is seen as a living being.  However, in some Hindu traditions, the beginning of personhood 
begins not at conception, but between three and five months of gestation.  A Hindu monk named 
Tyaganada best described a perspective on issues related to stem cells.  In Hinduism, the soul is the 
spiritual component of the personality which is separate from the mind and body; life and death are 
inseparable and intertwined. Tyaganada, when describing karma, wrote that the survival of one living 
organism is often at the expense of another living creature, thus when the destruction of embryos for ES 
cell research is done for the greater good, Hindus will accept ES cell research as ethically justified 
(Tyaganada, 2002). 
 In Buddhism, there are two main tenets similar to Hinduism. These are prohibition against 
harming or destroying others (Ahisma), and the pursuit of knowledge (Prajna) and compassion (karua). 
These tenets divide Buddhists on the issue of ES cell research (Walters, 2004). On one side, some 
Buddhists think that ES cell research fulfills the virtues of seeking knowledge and ending human 
suffering.   But in stark contrast, other Buddhists believe that it is a violation of harming others (the 
embryo).  Buddhism agrees with Hinduism on the theory of re-birth and considers any intentional 
destruction of embryos to obtain human ES cells as morally not permitted in view of re-birth (Keown, 
2001; Keown 2004). 
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Chapter-3 Conclusions 
 
 The embryonic stem cell ethical debate has come to center around how a different individuals 
view the status of the human embryo. Because some major religions view early embryos as human 
beings with full moral rights, they oppose ES cell research.  Catholicism, as well as Hinduism and 
Buddhism lead this camp by teaching that life begins at conception. The destruction of human embryos 
to these religions is akin to murder and euthanasia, because the embryo is considered a living human 
person.  In contrast, Judaism supports ethically justifiable research using embryos for research and 
therapeutic purposes anytime before the 41st day after conception, because of beliefs in their biblical 
and Talmudic teachings that ensoulement does not begin until day 40.  The majority of Muslims believe 
that personhood is an ongoing developmental process, and support the ethically regulated use of ES 
cells in research as long as it is being done to create new organs and tissues for treatment purposes and 
prior to “ensoulment” at day 120.  In general, none of these religions condone research that results in 
the destruction of potential human lives, but it is what each religion considers potential human life 
which constitutes the difference between their teachings. 
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Chapter 4:  Stem Cell Legalities  
 
U.S. and International Stem Cell Political Policies  
 
 
Introduction 
 
Stem cell research has risen to become one of the hottest, most highly controversial subjects in 
the 21st century.  In particular, embryonic stem cells (ESCs) have come to the forefront of most debates 
because human embryos are usually destroyed to obtain them.   As is typical of any controversial 
technology, the debates have influenced the creation of many laws and regulations to govern stem cell 
research around the world.  In the United States especially, the public has played a huge part in the 
politics of the issue, and this topic has truly influenced several of the past elections. The presidencies of 
Clinton, Bush, and most recently Obama, have all implemented new policies, aiding or hindering 
progress in stem cell research, depending on their ethical beliefs.    
U.S. Stem Cell Policies 
 
Most embryonic stem cell research in the past has occurred through in vitro fertilization (IVF).  
The IVF embryos are grown about 5 days to the blastocyst stage from which the ES cells are obtained, 
which destroys the embryo.  During IVF (as discussed in Chapter-3) from its first use in humans in the 
early 1960s until now, excess IVF embryos originally created for reproductive purposes were discarded 
by the clinic.  As science progressed, researchers began to use these discarded embryos to produce new 
embryonic stem cell lines.  To date, over 100 new embryonic cell lines have been created in the U.S., and 
nearly 300 developed in the world, as shown in Figure-10 (Abbott, 2006).  
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Figure 10: World Map Showing the Number of Embryonic Stem Cell Lines Created 
as of 2006.  Each box shows the number of human ES cell lines derived in a country 
(Abbott et al., 2006). 
 
 In 1973, a decision by the United States Supreme Court in Roe v. Wade, to legalize certain types 
of abortions, allowed fetal tissue to be used for research purposes and fed the fires of the ethical debate 
(Vestal, 2008).  In 1979, under President Carter, due to a large amount of pressure from anti-abortion 
groups, the Health and Human Services Department disbanded an advisory board that reviewed 
federally funded research on human sperm, eggs, and embryos (Smith, 1989).  Because of strong anti-
abortion sentiments, Ronald Reagan, and later George Bush, enacted policies to block federal funding 
for all research on human embryos (Kleiner, 1994).  In the 20 years since, stem cell research policies in 
the U.S. have been on a roller coaster ride. 
 
The Clinton Administration 
 
The Clinton administration saw the first real progress made toward uninhibited stem cell 
research policies since the initial discovery of the cells. Thirteen years after the Carter Administration 
Health and Human Services advisory board (mentioned above) was eliminated, President Clinton 
announced that he would lift the ban on embryo research.  He gave the National Institutes of Health 
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(NIH) the task of drafting guidelines for studies in this field (Kleiner, 1994). In 1994, the NIH established 
the Human Embryo Research Panel to develop methods that researchers should use to obtain embryos, 
and to determine the scope of ethical embryo research (Green, 1995). The panel consisted of 19 
scientists, physicians, ethicists, lawyers, and community representatives (Green, 1995). 
In November of 1994, the panel presented its guidelines.  Research could be allowed if the 
embryos were less than 14 days old.  The research could create IVF embryos solely for research 
purposes, and were not limited to surplus embryos from IVF reproductive clinics.  The NIH guidelines 
were acceptable under the stipulation that the researchers had to show their work promised 
outstanding scientific and therapeutic value (Report, 1994). The NIH voted to adopt the guidelines, but 
on the day of the vote, President Clinton issued an Executive Order that the scientists could not create 
new human embryos solely for research.  As a result, researchers could only use embryos left over from 
reproductive IVF treatments (Clinton, 1994).  
President Clinton strongly supported stem cell research for a reason, both personal and political. 
His good friend and chief of staff Erkines Bowles had two children that suffered from diabetes, and 
Clinton thought that embryonic stem cell research had the potential to lead to breakthroughs in many 
diseases, including diabetes (Clinton, 2004).  Many conservatives, however, thought that Clinton’s 
decisions were emotionally driven because of this, and did not think that he had the scientific working 
knowledge of stem cells to make such claims. 
In 1995, Congress overrode certain aspects of Clinton’s decision, preventing NIH from funding 
any research that harms or destroys human embryos (Vestal, 2008).  Clinton’s response was to tell the 
country that he did not approve of the direction congress was taking the research.  
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The Bush Administration 
 
In 2001, the election of George W. Bush brought many changes to stem cell research.  Being a 
devout Christian (and strongly influenced by the Catholic Pope), he firmly believed that life begins at 
conception with the very early human embryo (Dunn, 2005). His religion became a dominant force 
during his presidency that influenced him against the advancement of stem cell research.   On August 9, 
2001, President Bush announced that he would not allow any federal funding to derive new embryonic 
stem cell lines after that date (Pizzi, 2002). This put up a huge barrier for embryonic stem cell 
researchers because they could no longer afford to derive new ES cell lines on their own, so they had to 
obtain their embryos from private companies.  Three months later, the Bush administration ordered an 
official withdrawal of funding guidelines that President Clinton had authorized.  In doing this, he became 
the first president to reduce the amount of legal stem cell research from what the previous president 
had established (Dunn, 2005). Bush continued to shoot down any legislation that would loosen his 
restrictive guidelines on stem cell research.  He issued presidential vetoes on two separate occasions, 
one in response to a 2006 vote by the U.S. Senate to overturn his 2001 law, and the next in 2008 in 
response to another bill from the Senate to enhance stem cell research (Johnson & Williams, 2006). 
President Bush held firmly in his beliefs that ES cell research is not moral and the destruction of human 
life for research will not be tolerated.  
 
Individual States Stem Cell Policies 
 
During the Bush administration, there were many clashes between the President and Congress 
over stem cell research.  But that did not stop the advancement of stem cell research.  One could even 
say that Bush’s vetoes over the Senate led to local innovations in stem cell research.  After dealing with 
the federal ban for many years, individual states began to allocate huge amounts of money into their 
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own research.  Most notably, California and Massachusetts, have poured immense sums of money into 
stem cell research, although the total dollars can not match what the federal government can do. 
In November 2004, voters in California passed Proposition 71 to fund adult and embryonic stem 
cell research, and to establish the International Stem Cell Institute in San Francisco.  The proposition 
authorized the issuance of state bonds in the amount of $3 billion, beginning in 2005, not to exceed sale 
of over $350 million per year.  Although this state proposition remains one of the most ambitious of the 
various states seeking funding, and some Training Grants have been awarded, the award of larger 
research grants has been slowed by litigation.  As a result, the Governor of California decided to loan the 
International Stem Cell Institute $150 million in August 2006, and the institute continues to seek 
proposals.  The California Institute of Regenerative Medicine (CIRM), which administers the state stem 
cell research program, developed a Scientific Strategic Plan which was approved by its governing board 
in December2006.  It is estimated that CIRM spent over $622 million through the fiscal year 2008-09 
(Hayden, 2008). 
In Massachusetts, after overriding Governor Mitt Romney’s veto of a measure aimed at 
supporting human embryonic stem cell research in the state, Massachusetts legislators added two new 
sections to the statutes on stem cell research (Massachusetts… 2005). The first statute created an 
Institute for Stem Cell Research and Regenerative Medicine at the University of Massachusetts Medical 
Center (Worcester), with an appropriation of $1,000,000 to be spent on the stem cell biology core. The 
second statute established a Life Sciences Center to promote life sciences research in advanced and 
applied sciences, including but not limited to stem cell research, regenerative medicine, biotechnology, 
and nanotechnology.  The statute also created the Life Sciences Investment Fund to make 
appropriations, allocations, grants or loans to leverage development and investments in stem cell 
research and other areas.  $10,000,000 was appropriated to the fund.  Massachusetts is now a leading 
force in stem cell research in the U.S.  
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In order for stem cell research to advance, more trained scientists need to be trained in the 
United States.  Fortunately, many individual state’s bonds directly support scientist trainings in stem 
cell research, which indirectly overturns the federal veto by President Bush. 
 
Current U.S. Stem Cell Policies under the Obama Administration 
 
In January 2009, President Barack Obama was inaugurated and ushered in a new era of stem cell 
research.  Researchers whose work had been shackled during the 8 long years of Bush’s administration 
finally rejoiced when Obama signed an executive order for the NIH to develop guidelines and regulations 
to govern federally funded human embryonic stem cell research.  He stated that “We will vigorously 
support scientists who pursue this research, and we will aim for America to lead the world in the 
discoveries it one day may yield” (Hayden, 2009). He also stated that “At this moment, the full promise 
of stem cell research remains unknown, and it should not be overstated, but scientists believe that these 
tiny cells may have the potential to help us understand, and possibly cure, some of our most devastating 
diseases and conditions” (Childs & Stark, 2009). 
The changes that just occurred in the US Federal Administration following the election of 
President Obama are substantial and important. Given the new federal administrative backing, there will 
be an escalation of clinical trial submissions involving pluripotent ESCs, multipotent placental, and adult 
and fetal stem cells. The need for new investments for clinical trial support will be a key bottleneck, 
unless the government and health insurance industry joins pharmaceutical and biotechnology industries 
to carry out the large variety of trials expected. Academic and medical research centers are also 
expected to be involved in the translation and clinical trial processes which heralds new opportunities 
for teamwork approaches for these new cell therapies (Trounson, 2009). 
The NIH estimates the number of new embryonic stem cell lines to be anywhere from 400 to 
1000. These lines are vastly different from the 21 lines originally eligible for federal funding during the 
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Bush administration.  A large amount of these new lines have been created from embryos with genetic 
predispositions to specific diseases making them much more relevant to preclinical studies (Hayden, 
2009). In July 2009, the NIH approved its modified guidelines for stem cell research.  One key debate 
point was the source of the embryos.  Most scientists wanted federal funding for IVF embryos created 
solely for research purposes, but the final recommendation (in a nod to their ethically sensitive nature) 
was to allow only excess IVF embryos created for reproductive purposes. 
The public apparently supports these recent developments in stem cell legislation, as a majority 
(currently 57%) have no qualms about ES cell research (Figure-11).  
 
 
Figure 11:  Gallup Poll Summary of Americans in Favor of ES Research.  
American public opinion on medical research using stem cells obtained from 
human embryos (Good, 2009). 
 
From tiny embryonic cells, to the large-scale physics of global warming, President Barack Obama 
urged researchers in 2009 to follow science and not ideology as he abolished contentious Bush-era 
restraints on stem-cell research.  Obama’s message was clear; Science, which once propelled men to the 
moon, again matters in American life (Borenstein & Feller, 2009). 
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International Stem Cell Policies 
 
Although the United States is a big name in stem cell research, the rest of the world also has 
some key players, and continues to expand their research.  Some say that the U.S. is falling behind other 
nations (Schmickle, 2008), so hopefully this will change under the Obama administration.  Many top U.S. 
researchers in the past decade moved to the U.K. because of their wide-open race to develop stem cells. 
Below in Figure-12 is a map of the globe showing the policies of various countries on stem cell research. 
 
 
 
Figure 12: Global Stem Cell Policies.  Shown is a global map denoting the 
location of various stem cell centers (black dots), as well as the stem cell 
policies (Hoffman, 2007). 
 
A number of countries are emerging as powerhouses in the field of stem cell research.  These 
include Great Britain, Australia, Sweden, and China.   Great Britain is the leader in embryonic stem cell 
research and has been for years.  This is largely due to effective regulation, which allows various forms 
of ES cell research, and instills a trust between scientists and the public.  Early on, Great Britain viewed 
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stem cell research as a lucrative opportunity, and took advantage of the scientific opportunity.  In the 
1980s, British Parliament organized a committee to specifically address stem cell ethical concerns and 
scientific research limitations.  The committee came to the conclusion that, “Scientists can ethically, use 
early embryos for research purposes, but any such research work should be strictly regulated.”  Since 
then they have continued to grow (Boyd et al., 2009). 
In 2002, Australia founded the Australian Stem Cell Centre to take advantage of the country’s 
significant strengths in the field of stem cell research. They passed the Research Involving Human 
Embryos Act in 2002, which allowed for research on excess IVF embryos, including using them to derive 
human embryonic stem cells.  Since then, they have derived over 30 separate embryonic stem cell lines 
(Stem Cell Research in Australia, 2009).  
Sweden has long been a world leader in stem cell research.  The main difference between 
Sweden and the U.S. is that it never had any difficulty allowing ES cell lines to be derived from excess IVF 
embryos. This is now allowed in the U.S. with federal funding because of the Obama Administration’s 
policies, but research was delayed for almost 10 years while Sweden continued throughout. 
With generous support and in a cultural environment where there are fewer moral dilemmas to 
using embryonic stem cells, China has been booming with research.  In 2002, scientists developed a 
method to genetically alter neural stem cells to reproduce indefinitely but still retain their ability to 
differentiate into neurons. China is rapidly advancing in the field of regenerative medicine, hoping to use 
stem cell research to cure and treat a myriad of diseases afflicting people across the globe. They were 
also the first country to conduct human stem cell trials, and presented a significant opportunity for 
Western companies who were brave enough to use a risky destination as a place to pursue the 
potentially lucrative sector of their biotech industry (Barnes, 2006).  
Hopefully under Obama’s new policies, any initial brain drain that may have started with U.S. 
scientists migrating to other countries has been halted.  However, real brain drains have occurred within 
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the U.S. as some top scientists migrated to Calilfornia and Massachusetts from other states not funding 
ES cell research during the Bush administration.  
 
 
Chapter-4 Conclusion 
 
In the past 30 years, we have seen stem cell research grow in leaps and bounds, but obviously 
this controversial technology has mandated laws that regulate its use.  I feel that in order to effectively 
mediate stem cell research, a country must completely support and maintain funding for the research at 
the federal level.  Although individual states can fill in from time to time, nothing moves an agenda 
forward faster than with federal approval.   In the United States, progress on stem cell research has 
directly reflected the elected administration at the time, and has had periods of less growth.  Since the 
Presidency changes so frequently compared to other countries, and holds strong powers with its 
executive vetos, the President’s views have had a strong effect on research.  In order for the United 
States to keep up with the rest of the world, Obama’s current favorable stem cell regulations must be 
maintained even in subsequent administrations, scientific eduction of the public must continue 
(including with this IQP project), and researchers and industry need to collaborate to fund expensive 
stem cell clinical trials. 
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PROJECT CONCLUSIONS 
 
 
 
 After researching the information for this IQP, I have developed several opinions 
regarding the use of stem cells. With regards to embryonic stem (ES) cells, I firmly believe that 
it is acceptable to work them because of the near limitless potential and applications they have 
for disease treatment and regenerative medicine. As long as ES cells continue to be an extremely 
controversial topic in society, I do agree with other researchers that adult stem cells (ASCs) 
should be used wherever possible, as long as they provide similar medical results to ES cells. 
One foreseeable problem with ASCs is that they are currently very hard to produce in mass 
quantities. If the limitations of ASC production hamper the treatment of a particular disease, I 
believe that ES cells should be used instead.  When ES cells are used, I believe they should be 
obtained from excess IVF embryos originally created for reproductive purposes, not from paid 
donors created solely for research purposes. Because the excess IVF embryos have donor 
consent, and are going to be destroyed anyways, the rest of society should benefit from them, 
instead of letting a valuable potential go to waste.  With respect to stem cell legislation, 
worldwide Sweden currently has the best policies supporting stem cells, and that country is 
considered a leader in the field.  In the U.S., hopefully with the recent favorable stem cell 
legislation under the Obama administration, and a continuation of these policies from this 
president to the next, the United States can remain one of the world leaders in the medicine of 
the 21
st
 century. 
 
